Cerus Corporation (NASDAQ:CERS) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01
| Second Amendment to Rights Agreement by and between Cerus Corporation and Equiniti Trust Company, dated March1, 2019. |
CERUS CORP Exhibit
EX-3.1 2 d681066dex31.htm EX-3.1 EX-3.1 Exhibit 3.1 CERTIFICATE OF ELIMINATION OF SERIES A PREFERRED STOCK AND SERIES C JUNIOR PARTICIPATING PREFERRED STOCK OF CERUS CORPORATION (Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware) CERUS CORPORATION,…
To view the full exhibit click here
About Cerus Corporation (NASDAQ:CERS)
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.